Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1C | P00326 | 3/20 | 0.45 |
| ▸ | ADH1A | P07327 | 3/20 | 0.45 |
| ▸ | ADH4 | P08319 | 2/20 | 0.45 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | ADH1B | P00325 | 2/20 | 0.36 |
| ▸ | ADH7 | P40394 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 2/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9661652 | 0.98 | ADH1C (0.48) | ADH1CADH1AADH4DNM1TSHR | |
| SCHEMBL9660235 | 0.98 | ADH1C (0.48) | ADH1CADH1AADH4DNM1TSHR | |
| SCHEMBL302861 | 0.98 | ADH1C (0.48) | ADH1CADH1AADH4DNM1TSHR | |
| SCHEMBL303029 | 0.98 | ADH1C (0.48) | ADH1CADH1AADH4DNM1TSHR | |
| SCHEMBL9660996 | 0.98 | ADH1C (0.48) | ADH1CADH1AADH4DNM1TSHR | |
| SCHEMBL270646 | 0.98 | ADH1C (0.48) | ADH1CADH1AADH4DNM1TSHR | |
| SCHEMBL9661097 | 0.98 | ADH1C (0.48) | ADH1CADH1AADH4DNM1TSHR | |
| SCHEMBL388595 | 0.98 | ADH1C (0.48) | ADH1CADH1AADH4DNM1TSHR | |
| SCHEMBL11337999 | 0.98 | ADH1C (0.48) | ADH1CADH1AADH4DNM1TSHR | |
| SCHEMBL272223 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 425 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1027351-A1 | PHENANTHROLINE DERIVATIVES | FIBROGEN, INC. (US) | 2000-08-16 | — | — | EP | claimed |
| WO-1999021860-B1 | PHENANTHROLINE DERIVATIVES | FIBROGEN INC (US) | 1999-08-05 | — | — | WO | claimed |
| US-5916898-A | ANTIFIBROPROLIFERTIVE, ENZYME INHIBITORS OF PYROLYL 4-HYDROXYLASE, ANTIARTHRITIC AGENTS | ZENECA LIMITED (GB) | 1999-06-29 | — | — | US | claimed |
| WO-1999021860-A1 | PHENANTHROLINE DERIVATIVES | FIBROGEN, INC. (US) | 1999-05-06 | — | — | WO | claimed |
| US-4844717-A | KETONE AND AMIDE | UNION OIL COMPANY OF CALIFORNIA (US) | 1989-07-04 | — | — | US | claimed |
| US-4743273-A | AMIDE AND KETONE, ANTIDEPOSIT AGENTS | UNION OIL COMPANY OF CALIFORNIA (US) | 1988-05-10 | — | — | US | claimed |
| EP-3512849-B1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDIN-3-CARBOXAMIDES AND THEIR USE | BAYER AG (DE) | 2021-06-23 | — | — | EP | disclosed |
| US-10927109-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-23 | — | — | US | disclosed |
| EP-3307741-B1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARIC M2 RECEPTOR | Bayer Pharma AG (DE) | 2020-10-28 | — | — | EP | disclosed |
| EP-3481823-B1 | 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | Bayer Pharma AG (DE) | 2020-10-28 | — | — | EP | disclosed |
| EP-3692991-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC M2 RECEPTOR | Bayer Pharma Aktiengesellschaft (DE) | 2020-08-12 | — | — | EP | disclosed |
| EP-2955181-B1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | NISSAN CHEMICAL CORP (JP) | 2019-10-30 | — | — | EP | disclosed |
| US-10435403-B2 | Positive allosteric modulators of muscarinic M2 receptor | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-08 | — | — | US | disclosed |
| US-5290934-A | Benzoheterocyclic compounds | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-03-01 | — | — | US | disclosed |
| EP-0565132-A2 | Benzoheterocyclic compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-10-13 | — | — | EP | disclosed |
| EP-0517262-A1 | Trifluorothymidine derivatives, process for producing the same and anti-cancer agent containing the same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1992-12-09 | — | — | EP | disclosed |
| US-4844717-A | KETONE AND AMIDE | UNION OIL COMPANY OF CALIFORNIA (US) | 1989-07-04 | — | — | US | disclosed |
| EP-0287951-A2 | 7-Piperazinyl- or 7-Morpholino-4-oxo-quinoline-3-carboxylic acid derivatives, their preparation and their use as antimicrobial agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-10-26 | — | — | EP | disclosed |
| US-4743273-A | AMIDE AND KETONE, ANTIDEPOSIT AGENTS | UNION OIL COMPANY OF CALIFORNIA (US) | 1988-05-10 | — | — | US | disclosed |
| US-4217111-A | REDUCING OCTANE REQUIREMENT | CHEVRON RESEARCH COMPANY (US) | 1980-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435403-B2 | Positive allosteric modulators of muscarinic M2 receptor | CHRM2, CHRM1, CHRM3 | ADH1C 2210/4885ADH1A 2432/4885ADH4 2447/4885 |
| US-10927109-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | AADAC, GLS, NAT1 | ADH1C 203/4885ADH1A 265/4885ADH4 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.